Cardiovascular safety of oral semaglutide in patients with type 2 diabetes: Rationale, design and patient baseline characteristics for the PIONEER 6 trial

Stephen C. Bain*, Ofri Mosenzon, Rosario Arechavaleta, Pawel Bogdański, Abdurrahman Comlekci, Agostino Consoli, Chaicharn Deerochanawong, Kathleen Dungan, Maria C. Faingold, Michael E. Farkouh, Denise R. Franco, Jeppe Gram, Cristian Guja, Pankaj Joshi, Rachid Malek, Juan F. Merino-Torres, Michael A. Nauck, Sue D. Pedersen, Wayne H.H. Sheu, Robert J. SilverCees J. Tack, Nikhil Tandon, Ole K. Jeppesen, Mette Strange, Mette Thomsen, Mansoor Husain

*Corresponding author for this work

Research output: Contribution to journalJournal articleResearchpeer-review

157 Downloads (Pure)

Fingerprint

Dive into the research topics of 'Cardiovascular safety of oral semaglutide in patients with type 2 diabetes: Rationale, design and patient baseline characteristics for the PIONEER 6 trial'. Together they form a unique fingerprint.

Medicine & Life Sciences